Csl and arcturus therapeutics' arct-154 demonstrates non-inferiority to original strain and superior immunogenicity to omicron ba.4/5 variant compared to first-generation mrna vaccine booster

Study conducted by meiji seika pharma in japan data follow approval of the world's first self-amplifying messenger rna (sa-mrna) covid-19 vaccine for adults by japan ministry of health, labor and welfare the randomized, double-blind, active-controlled study, conducted at 11 sites in japan, was designed to compare the immunogenicity and tolerability of the sa-mrna vaccine arct-154 with comirnaty ® phase 3 study published in the lancet infectious diseases king of prussia, pa. and san diego , dec. 21, 2023 /prnewswire/ -- global biotechnology leader csl (asx:csl; usotc:cslly) and arcturus therapeutics (nasdaq: arct) today announced the publication in lancet infectious diseases of a phase 3 study showing that a booster dose of arct-154, a novel, self-amplifying messenger rna (sa-mrna) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original wuhan-hu-1 virus strain,  and a superior immune response against omicron ba.4/5 subvariant of sars-cov-2 virus compared to a booster dose of the conventional mrna vaccine comirnaty®.
ARCT Ratings Summary
ARCT Quant Ranking